Nomograms predicting prognosis of patients with pathological stages T1N2-3 and T3N0 gastric cancer

Figure 1 Survival curve analyses for patients with pT1N2-3 and pT3N0 GC. A: Overall survival curves for all patients; B: Overall survival curves for pT1N2-3 patients with and without postoperative chemotherapy; C: Overall survival curves for pT3N0 patients with and without postoperative chemotherapy.

Figure 2 Receiver operating characteristic curves of clinicopathological factors of patients with pT1N2-3 and pT3N0 GC. A: Assessing the prognosis of patients with pT1N2-3 GC; B: Assessing the prognosis of patients with pT3N0 GC. CEA: Carcino-embryonic antigen; mLNR: Metastatic lymph node ratio; BMI: Body mass index.

Figure 3 Survival curve subgroup analyses of patients. A: Overall survival curves for patients with prealbumin ≤ 222.35 mg/L and prealbumin > 222.35 mg/L in the pT1N2-3 group; B: Overall survival curves for patients with carcino-embryonic antigen (CEA) ≤ 3.17 ng/mL and CEA > 3.17 ng/mL in the pT1N2-3 group; C: Overall survival curves for patients with metastatic lymph node ratio (mLNR) ≤ 0.28 and mLNR > 0.28 in the pT1N2-3 group; D: Overall survival curves for patients with low risk, moderate risk, and high risk in the pT1N2-3 group; E: Overall survival curves for patients aged ≤ 60 years and aged > 60 years in the pT3N0 group; F: Overall survival curves for patients with body mass index (BMI) ≤ 22.48 kg/m² and BMI > 22.48 kg/m² in the pT3N0 group; G: Overall survival curves for patients with partial gastrectomy and total gastrectomy in the pT3N0 group; H: Overall survival curves for patients with low risk, moderate risk, and high risk in the pT3N0 group. CEA: Carcino-embryonic antigen; mLNR: Metastatic lymph node ratio; BMI: Body mass index.

Figure 4 Nomogram models for predicting the survival of patients with pT1N2-3 and pT3N0 GC. A: Nomogram model predicting the 3- and 5-year survival of patients with pT1N2-3 GC; B: Receiver operating characteristic curve (ROC) of the nomogram model for predicting the 3-year survival of patients with pT1N2-3 GC; C: ROC of the nomogram model for predicting the 5-year survival of patients with pT1N2-3 GC; D: Nomogram model for predicting the 3- and 5-year survival of patients with pT3N0 GC; E: ROC of the nomogram model for predicting the 3-year survival of patients with pT3N0 GC; F: ROC of the nomogram model for predicting the 5-year survival of patients with pT3N0 GC. CEA: Carcino-embryonic antigen; mLNR: Metastatic lymph node ratio; BMI: Body mass index.

Figure 5 Calibration plots for the nomograms. Correlation between the predicted probabilities based on the nomograms and actual values is shown. A: 3-year survival of patients with pT1N2-3 GC; B: 5-year survival of patients with pT1N2-3 GC; C: 3-year survival of patients with pT3N0; D: 5-year survival of patients with pT3N0 GC.